'Storm in a teacup': Why the Imugene share price is lifting 14% today

What did Imugene reveal in its letter to shareholders today?

| More on:
Nothing to see here, just a storm in a teacup as far as this boy and girl are concerned, sipping tea in their living room.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares are soaring nearly 14% today 
  • The S&P/ASX 200 Health Care Index, in contrast, is slipping nearly 1% 
  • The company's executive chair and CEO wrote to shareholders highlighting the company is "as strong as ever" 

The Imugene Limited (ASX: IMU) share price is soaring ahead today.

At the time of writing, Imugene shares are swapping hands for 22.8 cents, a 13.75% gain. In contrast, the S&P/ASX 200 Health Care Index (ASX: XHJ) is 0.87% in the red today. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is falling 0.1%.

Let's take a look at the letter from the company to shareholders released today.

Imugene share price lifts

Imugene has written to shareholders to discuss the company's share price in the last few months. For perspective, Imugene shares have dived 43% year to date.

Company leaders said Imugene is "as strong as it has ever been in its history". Imugene highlighted it has $100 million in cash and three unique platform technologies supporting six unique assets.

Imugene informed shareholders it expects to have 10 clinical studies supported by five to six United States Food and Drug Administration (FDA) investigational new drug applications. The drugs are targeting greater than 10 disease areas. The company also has two supply agreements with major pharmaceutical companies and two industry collaborations.

Imugene advised the market that multiple shareholders have reached out to the company about the recent cancelling of a supply agreement with MSD. On 2 May, the company's share price plunged nearly 14% on the back of this news. In a letter dated today, executive chair Paul Hopper and CEO and managing director Leslie Chong said:

The reaction to this has been out of all proportion to the news, and is really a storm in a teacup.

We recently announced that this trial is open ahead of schedule and can be expedited by obtaining the drug elsewhere, the cost of which is not material.

Turbulent times

Imugene noted "we are living in turbulent times" and biotech share prices have dropped dramatically since December last year. The company highlighted the sector has plunged about 65% from its peak in February 2021. Furthermore, April was the worst month on record for US biotech shares since 1997. Hopper and Chong added:

In addition, investors around the world have been spooked by the Ukraine Russia tensions, hawkish comments from the US Federal reserve, stubborn inflation and a worsening COVID situation in China.

Hopper and Chong said they remain and will continue to be large shareholders of the company and emphasised the "exciting times" ahead.

Share price snapshot

The Imugene share price has descended nearly 44% in the past year, but it is up 1.1% in a month.

In comparison, the benchmark ASX index has returned 2% over the past year.

In the past week alone, Imugene shares have surged 30%.

Imugene has a market capitalisation of $1.16 billion based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »